As mentioned in [102,117,127] the experimental analysis on HER2+ patients suggests that CD8+ T cell-mediated cytotoxicity and PD-L1 expression together may predict improved outcome in HER2+ BC patients under combined chemotherapy and HER2-targeted therapy [102]. The gene discussed is ERBB2; the disease is breast cancer.